Zacks: Analysts Expect China Biologic Products Holdings Inc (NASDAQ:CBPO) Will Announce Earnings of $0.70 Per Share

Wall Street analysts forecast that China Biologic Products Holdings Inc (NASDAQ:CBPO) will announce earnings per share of $0.70 for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $0.76 during the same quarter last year, which indicates a negative year over year growth rate of 7.9%. The business is expected to announce its next quarterly earnings results on Wednesday, March 4th.

On average, analysts expect that China Biologic Products will report full year earnings of $4.17 per share for the current financial year, with EPS estimates ranging from $3.94 to $4.40. For the next fiscal year, analysts expect that the company will report earnings of $4.38 per share, with EPS estimates ranging from $4.30 to $4.45. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow China Biologic Products.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings results on Wednesday, November 13th. The biopharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.52. China Biologic Products had a return on equity of 8.56% and a net margin of 29.46%. The company had revenue of $136.10 million for the quarter. During the same quarter in the previous year, the business posted $0.96 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis.

Several brokerages have recently issued reports on CBPO. Zacks Investment Research lowered China Biologic Products from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. ValuEngine upgraded China Biologic Products from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Finally, BidaskClub lowered China Biologic Products from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. China Biologic Products has a consensus rating of “Hold” and an average price target of $92.67.

Shares of CBPO opened at $116.70 on Tuesday. China Biologic Products has a 52-week low of $70.00 and a 52-week high of $119.44. The business’s fifty day moving average is $115.06 and its 200-day moving average is $100.90. The firm has a market cap of $4.54 billion, a price-to-earnings ratio of 28.33, a PEG ratio of 7.01 and a beta of 1.18.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new stake in shares of China Biologic Products during the 2nd quarter valued at $6,477,000. Canada Pension Plan Investment Board acquired a new position in China Biologic Products during the 2nd quarter worth about $8,749,000. Robeco Institutional Asset Management B.V. acquired a new position in China Biologic Products during the 3rd quarter worth about $2,461,000. Vanguard Group Inc. lifted its holdings in China Biologic Products by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 950,421 shares of the biopharmaceutical company’s stock worth $90,575,000 after buying an additional 29,178 shares during the period. Finally, Paradice Investment Management LLC acquired a new position in China Biologic Products during the 2nd quarter worth about $373,000. 37.05% of the stock is currently owned by institutional investors.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: What is the Bid-Ask Spread?

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.